As ANDA Suit Venue Options Shrink, Del., NJ Rule For Now

By Ryan Davis (November 24, 2021, 6:09 PM EST) -- One year after the Federal Circuit limited venue options for patent suits over generic drugs, a new ruling has clamped down further. But so far, most cases are still being filed in Delaware and New Jersey, the traditional hot spots for pharmaceutical litigation.

In November 2020, the appeals court ruled in Valeant v. Mylan that patent suits against generic drugmakers must be filed where the company is incorporated or where it performed actions related to its Abbreviated New Drug Application, departing from prior decisions that such suits could effectively be filed anywhere.

Earlier this month, on the one-year anniversary of that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!